Bildkälla: Stockfoto

Xbrane Biopharma Q4 2023: Initial comments - Redeye

Redeye shares its initial view on Xbrane's year-end report, which was higher than anticiated on revenues but pretty much in line in terms of EBIT.

Redeye shares its initial view on Xbrane's year-end report, which was higher than anticiated on revenues but pretty much in line in terms of EBIT.
Börsvärldens nyhetsbrev
ANNONSER